Enzyme News and Research

RSS

Study reveals a promising method for treating multiple sclerosis

A research team led by neurobiologist Professor Claire Jacob has identified an important mechanism that can be used to control the restoration of myelin sheaths following traumatic injury and in degenerative diseases.

24 Aug 2020

Antihypertensives improve COVID-19 survival rates

Previous studies have also linked hypertension to severe coronavirus disease (COVID-19). Now, a new study by researchers at the University of East Anglia's Norwich Medical School has found that the risk of severe COVID-19 and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).

24 Aug 2020

Loss of supporting cells in olfactory epithelium causes loss of smell in COVID-19

In the current pandemic of COVID-19, many patients have reported symptoms of loss of smell and taste. The cellular basis of this phenomenon has not been satisfactorily explained so far. However, a new study published in the Briefings in Bioinformatics in August 2020 shows how this symptom is related to viral pathogenesis.

23 Aug 2020

Raccoon dogs potential intermediate host for SARS-CoV-2

Researchers at the Friedrich Loeffler Institute in Germany have conducted a study demonstrating that raccoon dogs were a potential intermediate host in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Aug 2020

Genomic analysis reveals vulnerability of many animal species to SARS-CoV-2 infection

Humans are not the only species facing a potential threat from SARS-CoV-2, the novel coronavirus that causes COVID-19, according to a new study from the University of California, Davis.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

Bioinformatics identifies key genes and cellular pathways in COVID-19

The COVID-19 pandemic is showing no signs of waning or extinction anytime soon. Now, a new study published on the preprint server bioRxiv* in August 2020 shows a new bioinformatics approach to studying the pathogenesis of this disease, by uncovering the differentially expressed genes (DEGs) and cell signaling pathways that cause the disease characteristics. This will help develop better therapies to counter the effects of these genes.

20 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

A metabolic enzyme shows great potential as target for immunotherapies

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.

20 Aug 2020

Cells lining the nose are key entry point for coronavirus, shows study

Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.

20 Aug 2020

SARS-CoV-2 hijacks antiviral factors to promote infection in human lung cells

Now, a new study published in the preprint server bioRxiv in August 2020 shows that under conditions resembling those in vivo, IFNs may promote efficient viral invasion instead.

20 Aug 2020

Researchers use heparin to block co-receptor for SARS-CoV-2 infection

Researchers at the University of Amsterdam have conducted a study showing that heparan sulfate proteoglycans are important co-receptors that severe acute respiratory syndrome 2 (SARS-CoV-2) requires to infect host cells.

19 Aug 2020

Human microbiome trims mucosal glycans, influencing SARS-CoV-2 infection

An international team of researchers has conducted a study showing that differences in the human microbiome may influence the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

19 Aug 2020

Centralized medical records repository can perform data analysis and visualization

More than a decade ago, electronic medical records were all the rage, promising to transform health care and help guide clinical decisions and public health response.

19 Aug 2020

Study fills crucial knowledge gaps on myasthenia gravis

A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle.

19 Aug 2020

Study shows how bats survive the Ebola virus

A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people. This study is now available in Cell Reports.

19 Aug 2020

COVID immunity related to how bad you get it

Researchers at Stanford University in California have shown that severely ill patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop significantly higher levels of antibodies against the virus than asymptomatic individuals and outpatients.

18 Aug 2020

RNA-based therapeutic approach holds promise as potential cure for hereditary diseases

ETH Zurich scientists have developed an RNA molecule that can be used in bone marrow cells to correct genetic errors that affect protein production.

18 Aug 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.

18 Aug 2020

Researchers solve a long-held mystery of X chromosome inactivation

Researchers at Massachusetts General Hospital (MGH) have solved a mystery that has long puzzled scientists: How do the bodies of female humans and all other mammals decide which of the two X chromosomes it carries in each cell should be active and which one should be silent?

18 Aug 2020